Showing 801-810 of 10588 results for "".
Updates in Glomerular Disease
https://reachmd.com/programs/cme/updates-in-glomerular-disease/14891/Explore cases of IgAN, FSGS, and AAV to further your knowledge of the underlying mechanisms of glomerulonephritis and sclerosis and improve outcomes.Incorporating Targeted Therapies in Treatment Planning for AAV
https://reachmd.com/programs/cme/incorporating-targeted-therapies-in-treatment-planning-for-aav/14962/Our experts offer tips to effectively manage your patients with AAV & improve their quality of life by incorporating C5a receptor antagonist therapy.Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
https://reachmd.com/programs/cme/utilization-and-management-of-antibody-drug-conjugates-in-metastatic-breast-cancer-the-relationship-between-adcs-and-her2/14552/Are antibody-drug conjugates right for your patients with HER2 mBC? Our experts are breaking down the latest data, and they may surprise you.Cracking the Code of Obstruction: Unmet Needs in oHCM
https://reachmd.com/programs/cme/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Safety in oHCM Therapy: How and When to Transition Treatment?
https://reachmd.com/programs/cme/safety-in-ohcm-therapy-how-and-when-to-transition-treatment/56831/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Molecular Precision: How Myosin Inhibitors Redefine Control
https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.When ß-Blockers Fall Short in oHCM: Time for a New Approach?
https://reachmd.com/programs/cme/when-blockers-fall-short-in-ohcm-time-for-a-new-approach/54838/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.